lndium-1111 antimyosin scintigraphy inn the early detection of heart damage afterr anthracycline therapy in children Introduction n Despitee the firmly established early and late cardiotoxic side effects of anthracyclines, thesee drugs are among the most widely used agents for the treatment of childhood cancer.
1 - 22 The incidence and severity of clinical and subclinical cardiac damage after anthracyclinee therapy increases with increasing cumulative dose, additional radiotherapy andd female sex. 3 Moreover, children seem to be more susceptible than adults to the cardiotoxicc effects of anthracycline therapy, although there is considerable variation in thee individual susceptibility to these side effects. 4 Conventionall methods, such as radionuclear angiography and echocardiography, are not suitablee for investigating early cardiac damage because they are not sensitive enough;
i.e.,, a critical number of cells may be damaged before the functional myocardial impairmentt is detected. 5 Yet, early identification of children at risk for cardiac damage is essentiall because subsequent preventive measures can limit further myocardial damage.
Inn this setting lndium-111-antimyosin ( 111 ln-AM) scintigraphy may be of diagnostic use becausee it allows noninvasive detection of myocardial damage in vivo. The binding of thiss antibody to intracellular myosin takes place only when the sarcolemma is disrupted duee to cell damage. 6 A study of rats treated with doxorubicin showed a progressive increasee in myosin uptake with increasing severity of myocardial damage. A strongly positivee correlation was found between the intensity of myocardial uptake and the loss off contractile function. Immunohistochemical staining showed that ln-111 AM was localizedd exclusively in injured myocytes. 7 Studies with adult patients showed that the intensityy of ln-111 AM uptake was related to the cumulative dose of doxorubicin and thatt ln-111 AM uptake preceded changes in the ejection fraction. 8 ' 9 -
10
Theree have been no studies of ln-111 AM uptake in children and young adults treated withh anthracyclines. We performed a pilot study involving eight patients who were treatedd with doxorubicin to determine whether ln-111 AM scintigraphy can be used to detectt early cardiac damage during chemotherapy in children and in young adults.
Patientss and Methods

Patients s
Eightt patients with a tumor eligible for doxorubicin treatment were included in the study:: seven children and one young adult, with a mean age of 12 years (range 1-25 years).. The patient charac-teristics are listed in Table 1 Mbqq for patients aged 10-14 years, and 80 Mbq for patients older than 14 years.
Scintigraphyy was performed 48 hours after infusion of AM. We used a large field of view gammaa camera (Diacam Siemens) equipped with a medium energy collimator and a 20 percentt window set around both peaks of ln-111 at a preset time of 10 minutes. Scans weree stored in 128x128 frames for subsequent analysis. The scintigrams were interpreted quantitativelyy by an experienced nuclear physician unaware of the patient's condition andd echocardiographic results. Regions of interest for heart and lungs were drawn and a heart-to-lungg ratio (HLR) was calculated as the average counts per pixel in the myocardiumm divided by the average counts per pixel in the lungs. 11 The mean value of threee separate HLR evaluations was used as the HLR value of an ln-111 AM scintigram.
Echocardiography y
Echocardiogramss were made by a pediatric cardiologist and a technician before and afterr 3 weeks of doxorubicin administration as a part of the treatment protocol, using describedd a randomized trial in which adults were treated with epirubicine with or withoutt dexrazoxane, and cardiotoxicity was monitored by ln-111 AM scintigraphy and radionuclidee angiography. 13 With ln-111 AM scintigraphy they found a significant differencee between the two treatment groups in an early stage of anthracycline therapy, butt not when they measured the left ventricular ejection fraction by multigated radionuclidee angiography.
Inn this study we found evidence of myocardial injury as measured by ln-111 AM scintigraphyy in patients with a normal FS. These results are consistent with endomyocardiall biopsy findings and serum cardiac troponin concentrations measured in patientss receiving anthracycline therapy. 14 "
17
Inn 1983 Isner et al described histological signs of anthracycline cardiotoxicity in 52% of theirr patients even though these patients did not show changes in heart function. Thee results of this pilot study suggest that ln-111 AM scintigraphy can detect early myocardiall damage before conventional methods detect cardiac dysfunction in children treatedd with anthracyclines. In future clinical trials ln-111 AM scintigraphy can be used to identifyy patients at risk of subsequent cardiac sequelae and to measure the effect of cardioprotectivee agents.
